Geron Ownership
| GERN Stock | USD 1.64 0.03 1.80% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 662 M | Current Value 646 M | Avarage Shares Outstanding 232.8 M | Quarterly Volatility 161.5 M |
Geron |
Geron Stock Ownership Analysis
About 78.0% of the company shares are owned by institutional investors. The book value of Geron was currently reported as 0.46. The company recorded a loss per share of 0.27. Geron had not issued any dividends in recent years. The entity had 1058:1000 split on the 22nd of July 2014. Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. The company was incorporated in 1990 and is headquartered in Foster City, California. Geron Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people. To learn more about Geron call the company at 650 473 7700 or check out https://www.geron.com.Besides selling stocks to institutional investors, Geron also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Geron's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Geron's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Geron Quarterly Liabilities And Stockholders Equity |
|
Geron Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Geron is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Geron backward and forwards among themselves. Geron's institutional investor refers to the entity that pools money to purchase Geron's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 13.1 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 11.7 M | Woodline Partners Lp | 2024-12-31 | 11.6 M | Vestal Point Capital Lp | 2024-12-31 | 11 M | Darwin Global Management, Ltd. | 2024-12-31 | 9.6 M | Segall Bryant & Hamill | 2024-12-31 | 7.4 M | Eventide Asset Management, Llc | 2024-12-31 | 7.1 M | Millennium Management Llc | 2024-12-31 | 7 M | Braidwell Lp | 2024-12-31 | 7 M | Blackrock Inc | 2024-12-31 | 49.9 M | Vanguard Group Inc | 2024-12-31 | 33.5 M |
Geron Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Geron insiders, such as employees or executives, is commonly permitted as long as it does not rely on Geron's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Geron insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Geron Outstanding Bonds
Geron issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Geron uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Geron bonds can be classified according to their maturity, which is the date when Geron has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
When determining whether Geron offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Geron's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Geron Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Geron Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.27) | Revenue Per Share | Quarterly Revenue Growth 2.1 K | Return On Assets | Return On Equity |
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.